Expertise in
10
conditions

Dr. Curtis A. Baum

Gastroenterology
Cotton-O'Neil Digestive Health Center
720 SW Lane St, 
Topeka, KS 
Accepting New Patients
Expertise in
10
conditions
Cotton-O'Neil Digestive Health Center
720 SW Lane St, 
Topeka, KS 

Overview

Curtis Baum is a Gastroenterologist practicing medicine in Topeka, Kansas.

Dr. Baum is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Cronkhite-Canada Disease, Attenuated Familial Adenomatous Polyposis, Juvenile Polyposis Syndrome, Endoscopy, and Gastrostomy.

He is actively involved in clinical research, participating in 9 clinical trials. Dr. Baum is currently accepting new patients.

Graduate Institution

University Of Kansas School Of Med (Kc/wich/sal)

Specialties

Gastroenterology

Licenses

Internal Medicine in KS

Hospital Affiliations

University Of Kansas Health System - St Francis Campus
Stormont Vail Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cotton-O'Neil Digestive Health Center
720 SW Lane St, Topeka, KS 66606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
15
conditions
Dr. Ajay K. Bansal
Gastroenterology
Expertise in
15
conditions
Dr. Ajay K. Bansal
Gastroenterology
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (58.1 miles away)
913-588-1227
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Bansal is a Gastroenterologist practicing medicine in Kansas City, Kansas. Dr. Bansal is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Colorectal Polyps, Gastroesophageal Reflux Disease (GERD), Colonoscopy, and Endoscopy. Dr. Bansal is board certified in American Board Of Internal Medicine, Gastroenterology - 2004. Dr. Bansal is currently accepting new patients.

Expertise in
46
conditions
Dr. Shekhar K. Challa
Gastroenterology
Expertise in
46
conditions
Dr. Shekhar K. Challa
Gastroenterology
Referral may be required

University Of Kansas Health System St. Francis Campus

1700 SW 7th St, 
Topeka, KS 
 (0.3 miles away)
785-295-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shekhar Challa is a Gastroenterologist practicing medicine in Topeka, Kansas. Dr. Challa is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Visceromegaly, Diverticular Disease, Alcoholic Cirrhosis, Endoscopy, and Gastrectomy. Dr. Challa is currently accepting new patients.

Expertise in
48
conditions
Dr. Amit K. Rastogi
Gastroenterology
Expertise in
48
conditions
Dr. Amit K. Rastogi
Gastroenterology
Referral may be required

The University Of Kansas Hospital

4000 Cambridge Street, 
Kansas City, KS 
 (58.2 miles away)
913-588-1227
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Amit Rastogi is a Gastroenterologist practicing medicine in Kansas City, Kansas. Dr. Rastogi is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Jaundice, Colorectal Polyps, Hereditary Pancreatitis, Endoscopy, and Colonoscopy. Dr. Rastogi is board certified in American Board Of Internal Medicine, Gastroenterology - 2004. Dr. Rastogi is currently accepting new patients.

Frequently Asked Questions about Dr. Curtis A. Baum

How do I make an appointment with Dr. Curtis A. Baum?

You can book an appointment with Dr. Curtis A. Baum by calling their office at 785-270-4850. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Curtis A. Baum a top-rated expert for Cronkhite-Canada Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Curtis A. Baum is classified as an Advanced expert for Cronkhite-Canada Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Curtis A. Baum specialize in?

While Dr. Curtis A. Baum is a Gastroenterology, they have specific expertise in Cronkhite-Canada Disease, Attenuated Familial Adenomatous Polyposis, and Juvenile Polyposis Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Curtis A. Baum accept my insurance?

Dr. Curtis A. Baum accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 785-270-4850 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baum's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 26 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile